Neoprobe cuts staff after regulatory rebuffs:
This article was originally published in Clinica
Executive Summary
Neoprobe is to cut staff by 20% in order to reduce its 1998 projected losses to $12 million. The US company wishes to see operating costs fall by 30%, from $30.4 million. Last year European approval for the RIGScan CR49 antibody colorectal cancer detection was delayed (see Clinica No 766, p 16) and in January the FDA requested further information on side effects of the radioactive-tagged marker (see Clinica No 790, p 12).
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.